Deerfield Management Company, L.P. (Series C) 4 D Molecular Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.84 Billion
- Q1 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 8,821 shares of FDMT stock, worth $185,152. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,821Holding current value
$185,152% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding FDMT
# of Institutions
157Shares Held
50.3MCall Options Held
718KPut Options Held
370K-
Vr Adviser, LLC New York, NY4.4MShares$92.4 Million12.03% of portfolio
-
Black Rock Inc. New York, NY4.28MShares$89.9 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.92MShares$82.3 Million3.74% of portfolio
-
Janus Henderson Group PLC London, X03.2MShares$67.1 Million0.06% of portfolio
-
Goldman Sachs Group Inc New York, NY3.06MShares$64.2 Million0.02% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $680M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...